4.7 Article

First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 15_suppl, Pages 2504-2504

Publisher

American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2010.28.15_suppl.2504

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available